Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy

CAR (chimeric antigen receptor) T cell therapy has shown clinical success in treating hematological malignancies, but its treatment of solid tumors has been limited. One major challenge is on-target, off-tumor toxicity, where CAR T cells also damage normal tissues that express the targeted antigen....

Descripción completa

Detalles Bibliográficos
Autores principales: Bangayan, Nathanael J., Wang, Liang, Burton Sojo, Giselle, Noguchi, Miyako, Cheng, Donghui, Ta, Lisa, Gunn, Donny, Mao, Zhiyuan, Liu, Shiqin, Yin, Qingqing, Riedinger, Mireille, Li, Keyu, Wu, Anna M., Stoyanova, Tanya, Witte, Owen N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666036/
https://www.ncbi.nlm.nih.gov/pubmed/37963244
http://dx.doi.org/10.1073/pnas.2312374120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666036/
https://www.ncbi.nlm.nih.gov/pubmed/37963244
http://dx.doi.org/10.1073/pnas.2312374120

Ejemplares similares